Zong H, Zou JQ, Huang JP, Huang ST. Potential role of long noncoding RNA RP5-881L22.5 as a novel biomarker and therapeutic target of colorectal cancer. World J Gastrointest Oncol 2022; 14(11): 2108-2121 [PMID: 36438707 DOI: 10.4251/wjgo.v14.i11.2108]
Corresponding Author of This Article
Hua Zong, Doctor, Department of Gastrointestinal Surgery, The Third People’s Hospital of Shenzhen, No. 29 Bulan Road, Shenzhen 518000, Guangdong Province, China. zonghua@mail.sustech.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hua Zong, Jian-Qiang Zou, Jian-Peng Huang, Shi-Ting Huang, Department of Gastrointestinal Surgery, The Third People’s Hospital of Shenzhen, Shenzhen 518000, Guangdong Province, China
Author contributions: Zong H designed the project, wrote the paper and acquired the data; Zou JQ and Huang JP analyzed and interpreted the data; Huang ST modified the language of the article.
Supported bythe Shenzhen Third People’s Hospital, No. G2022117.
Institutional review board statement: The study was reviewed and approved by the Shenzhen Third People's Hospital (Approval No. G2022117).
Informed consent statement: Patients were not required to give informed consent to the study.
Conflict-of-interest statement: All authors declare that there is no conflict of interest in this work.
Data sharing statement: All data are publicly available for sharing use.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hua Zong, Doctor, Department of Gastrointestinal Surgery, The Third People’s Hospital of Shenzhen, No. 29 Bulan Road, Shenzhen 518000, Guangdong Province, China. zonghua@mail.sustech.edu.cn
Received: June 25, 2022 Peer-review started: June 25, 2022 First decision: August 30, 2022 Revised: September 13, 2022 Accepted: October 19, 2022 Article in press: October 19, 2022 Published online: November 15, 2022
ARTICLE HIGHLIGHTS
Research background
Colorectal cancer is one of the most common malignant tumors in the world. Long noncoding RNAs (lncRNAs) are involved in many normal human physiological functions and pathogenic processes of diseases.
Research motivation
LncRNAs may be used as molecular markers for more accurate prediction of colorectal cancer prognosis. The molecular mechanisms of lncRNAs involved can impact colorectal cancer prognosis and impact the tumor immune microenvironment. Further research into these questions is needed.
Research objectives
To explore the differential expression analysis of mRNAs and lncRNAs in the colorectal cancer and to determine the association between RP5-881L22.5 expression and the tumor immune microenvironment.
Research methods
We analyzed the immune cell microenvironment through the bioinformatics combined with clinical data and cell experiments to verify the results.
Research results
RP5-881 L22.5 expression led to a difference in prognosis, which warrants further research on immunotherapy of advanced tumors with RP5-881 L22.5 as a marker.
Research conclusions
RP5-881 L22.5 plays an important role in the pathogenesis of colorectal cancer.
Research perspectives
RP5-881 L22.5 may be an important research target for the treatment of colorectal cancer.
